Low dose TXA

ApprovedSmall molecule

BBoston Children's Hospital

Low dose TXA is one of 5 small molecule programs targeting Craniosynostosis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CraniosynostosisActive, not recruiting

CraniosynostosisApproved

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Craniosynostosis

#DrugCompanyPhaseTrials

Sevofluorane

TTamas Vegh, MD

Approved

1 2

Low dose TXA

BBoston Children's Hospital

Approved

1 3

High Dose TXA

BBoston Children's Hospital

Approved

1 4

Cyklokapron

AAmring

Preclinical

1 5

Ferrous Fumarate or Ferrostrane

UUniversity Hospital, Montpellier

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2030

Post-ApprovalNot yet recruiting

Gastrointestinal

NCT07303868

Post-ApprovalRecruiting

Gastrointestinal

NCT07303738

Not yet recruiting

Gastrointestinal

NCT06913621

Clinical

Trials by Indication[1]

Gastrointestinal3 trials

The Use of High Bile-binding Foods to Reduce Upper Gastrointestinal Bile Acid Concentrations (Aim 2)

Not yet recruiting·—·Phase 4·NCT07303868·66 enrolled

The Use of High Bile-binding Foods to Reduce Upper Gastrointestinal Bile Acid Concentrations (Aim 1)

Recruiting·—·Phase 4·NCT07303738·60 enrolled

The Use of High Bile-Binding Foods to Reduce Upper Gastrointestinal Bile Acid Concentrations (Aim 3)

Not yet recruiting·—··NCT06913621·138 enrolled

Craniosynostosis1 trial

The Efficacy and Population Pharmacokinetics of Tranexamic Acid for Craniosynostosis Surgery

Completed·—·Phase 4·NCT02188576·66 enrolled

Tranexamic Acid1 trial

Dose-Dependent Effects of Intraoperative Tranexamic Acid on Surgical Bleeding and Transfusion Requirements in Multilevel Thoracolumbar Spinal Surgery

Completed·—·N/A·NCT07288697·62 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Low dose TXA. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Low dose TXA compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Low dose TXA. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Boston Children's Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: BBoston Children's Hospital

Low dose TXA

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2030

Trials by Indication[1]

Gastrointestinal3 trials

Craniosynostosis1 trial

Tranexamic Acid1 trial

References

Drug Info

Quick Facts

Related News